U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07186686) titled 'Feasibility Study of AMENUCED Program in Type 2 Diabetes' on Sept. 02.
Brief Summary: Type 2 diabetes is characterized by progressive resistance to the effects of insulin, along with deficient insulin production. In Mexico, it affects 18.4% of adults and is the second leading cause of death. According to ENSANUT 2023, 74.2% of adults with diabetes have poor glycemic control. Achieving adequate glycemic control requires multiple interventions. The AMENUCED program is multicomponent and includes medical care, nutritional guidance, lifestyle support, and diabetes education. Each component has independently shown positive outcomes in d...